文献速递脑血管病认知障碍与痴呆

他达拉非治疗脑小血管病:ETLAS-2随机临床试验

Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial.
PubMed 文献 · Stroke · 2025-07-28

ETLAS-2为随机、安慰剂对照、双盲、平行II期试验,纳入76例脑小血管病且既往卒中或TIA患者,比较每日他达拉非20mg与安慰剂治疗3个月。主要结局为可行性(≥90%服药依从性),他达拉非组依从性显著低于安慰剂组且未达预设阈值,不良事件更常见;白质高信号体积有非显著下降趋势。

要点

  • 他达拉非组≥90%依从性26/38,安慰剂组31/33,OR 0.13(95%CI 0.03-0.69;P=0.030),未达预设阈值。
  • 他达拉非组不良事件发生率76%,安慰剂组36%,OR 5.49(95%CI 1.81-18.07;P=0.001)。
  • 按方案分析中他达拉非组白质高信号体积相对变化0.939(95%CI 0.881-1.001;P=0.054),认知、心理健康和血压无差异。

核心结论

  • 在脑小血管病患者中,他达拉非的依从性显著低于安慰剂,且未达到预设的依从性阈值。
  • 他达拉非治疗后白质高信号体积出现非显著下降,需更大规模、更长期且降低剂量的研究探索潜在获益。

研究设计与样本

  • ETLAS-2为随机、安慰剂对照、双盲、平行II期试验,比较每日他达拉非20mg与安慰剂治疗3个月。
  • 纳入76例脑小血管病且既往卒中或短暂性脑缺血发作患者,来自丹麦首都地区,2022至2024年。
  • 主要结局为可行性(≥90%研究药物依从性),采用以治疗组为协变量的二元逻辑回归模型计算。

主要发现

  • 他达拉非组38例中26例≥90%依从,安慰剂组33例中31例,OR 0.13(95%CI 0.03-0.69;P=0.030)。
  • 他达拉非停药者中女性占46%,男性仅16%。
  • 不良事件发生率他达拉非组76% vs 安慰剂组36%,OR 5.49(95%CI 1.81-18.07;P=0.001)。
  • 未调整按方案分析中,他达拉非组随访时白质高信号体积相对变化0.939(95%CI 0.881-1.001;P=0.054)。

关键数值与推荐

  • 主要结局可行性阈值:≥90%研究药物依从性。
  • 他达拉非组≥90%依从比例26/38,安慰剂组31/33,OR 0.13(95%CI 0.03-0.69;P=0.030)。
  • 不良事件OR 5.49(95%CI 1.81-18.07;P=0.001)。
  • 白质高信号体积相对变化0.939(95%CI 0.881-1.001;P=0.054)。

临床怎么用

  • 当前证据不支持对脑小血管病患者常规使用他达拉非20mg每日治疗。
  • 他达拉非在该人群耐受性较差,不良事件常见,女性停药比例更高。
  • 白质高信号体积的非显著下降提示需进一步研究更低剂量和更长疗程。

局限性

  • II期试验样本量小(76例),随访仅3个月。
  • 主要结局为可行性而非临床疗效,效力不足以检测影像或认知差异。
  • 白质高信号体积分析为未调整按方案分析,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: White matter hyperintensities and reduced cerebral blood flow are hallmarks of cerebral small vessel disease (CSVD). We tested the feasibility of daily treatment with the vasoactive drug tadalafil in patients with CSVD and its effects on cognition and imaging markers of CSVD. METHODS: The ETLAS-2 trial (Effect of Tadalafil in Lacunar Stroke) was a randomized, placebo-controlled, double-blind, parallel phase II trial testing 3 months of daily tadalafil 20 mg versus placebo in patients with CSVD and previous stroke or transient ischemic attack. Participants were included from the Capital Region of Denmark from 2022 to 2024. Outcomes were assessed at baseline and after 3 months. A binary logistic regression model with the treatment group as a covariate was used to calculate the primary outcome of feasibility (≥90% study drug compliance). Secondary outcomes included the Montreal Cognitive Assessment, magnetic resonance imaging markers of CSVD (Standards for Reporting Vascular Changes on Neuroimaging criteria), blood pressure, and adverse events. RESULTS: We included 76 participants (20 female, mean age, 68.0±8.9 years). Seventy-one initiated treatment, and 26 of 38 participants with tadalafil were ≥90% compliant versus 31 of 33 with placebo (odds ratio, 0.13 [95% CI, 0.03-0.69]; P=0.030). There was a female preponderance in tadalafil dropouts, with 46% of females stopping treatment, compared with only 16% of males. Adverse events occurred in 76% of participants with tadalafil versus 36% with placebo (odds ratio, 5.49 [95% CI, 1.81-18.07]; P=0.001). A trend toward lower white matter hyperintensity volume at follow-up was observed in the tadalafil group in the unadjusted per-protocol analysis (relative change, 0.939 [95% CI, 0.881-1.001]; P=0.054). No differences were observed in cognition, mental well-being, or blood pressure. CONCLUSIONS: In participants with CSVD, adherence to tadalafil was significantly lower than to placebo and did not meet the prespecified compliance threshold. We observed a nonsignificant reduction in white matter hyperintensity volume after tadalafil, which warrants larger and prolonged studies with reduced tadalafil doses to explore potential benefits in CSVD. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05173896.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Ölmestig J, Mortensen KN, Thomas MB, et al. Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial. Stroke. 2025. PMID: 40718899. doi:10.1161/STROKEAHA.125.051602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。